Pharsight

Drugs that contain Lorlatinib

1. Lorbrena patents expiration

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(9 years from now)

US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(12 years from now)

US11299500 PFIZER Crystalline form of lorlatinib free base hydrate
Oct, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 3, 2028
New Indication (I) Mar 3, 2024

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceriti...

Dosage: TABLET;ORAL

More Information on Dosage

LORBRENA family patents

Family Patents